Sudo Biosciences, a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced raising an additional $30 million in a second close of its Series B financing.
UPMC Enterprises is one of three new investors that helped to bring the total raised to approximately $147 million. Proceeds from the Series B investments will be used to advance two investigational TYK2 candidates into the clinic this year. This investment marks Enterprises’ first venture into the multiple sclerosis (MS) space.
Sudo’s CNS program is a potential first and best-in-class brain-penetrant TYK2 therapeutic that could significantly advance the treatment of both the relapsing and progressive forms of multiple sclerosis as well as neurodegenerative conditions such as Alzheimer’s Disease and Amyotrophic Lateral Sclerosis (ALS). Sudo is also developing a topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.
To learn more, read Sudo’s full press release, or the recent press releases here:
